Diversify Advisory Services LLC Grows Position in Affirm Holdings, Inc. (NASDAQ:AFRM)

Diversify Advisory Services LLC grew its stake in shares of Affirm Holdings, Inc. (NASDAQ:AFRM) by 17.5% during the 3rd quarter, Holdings Channel.com reports. The firm owned 107,379 shares of the company’s stock after acquiring an additional 15,993 shares during the period. Diversify Advisory Services LLC’s holdings in Affirm were worth $4,724,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in AFRM. Allspring Global Investments Holdings LLC increased its holdings in Affirm by 82.4% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,195 shares of the company’s stock valued at $36,000 after buying an additional 540 shares in the last quarter. ORG Partners LLC raised its holdings in Affirm by 80.0% during the second quarter. ORG Partners LLC now owns 1,240 shares of the company’s stock worth $37,000 after purchasing an additional 551 shares during the last quarter. Myecfo LLC boosted its position in Affirm by 5.0% during the third quarter. Myecfo LLC now owns 12,260 shares of the company’s stock worth $500,000 after purchasing an additional 589 shares in the last quarter. Commonwealth Equity Services LLC grew its holdings in Affirm by 5.7% in the second quarter. Commonwealth Equity Services LLC now owns 12,548 shares of the company’s stock valued at $379,000 after purchasing an additional 680 shares during the last quarter. Finally, ORG Wealth Partners LLC purchased a new position in shares of Affirm in the third quarter valued at $29,000. Hedge funds and other institutional investors own 69.29% of the company’s stock.

Insider Activity at Affirm

In other news, Director Keith Rabois sold 9,275 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $26.90, for a total transaction of $249,497.50. Following the transaction, the director now owns 64,348 shares of the company’s stock, valued at approximately $1,730,961.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director Keith Rabois sold 9,275 shares of Affirm stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $26.90, for a total value of $249,497.50. Following the completion of the transaction, the director now directly owns 64,348 shares of the company’s stock, valued at approximately $1,730,961.20. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Christa S. Quarles sold 14,400 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $40.02, for a total transaction of $576,288.00. Following the sale, the director now owns 141,903 shares in the company, valued at approximately $5,678,958.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,075 shares of company stock valued at $4,803,786 over the last ninety days. Corporate insiders own 13.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Morgan Stanley upgraded shares of Affirm from an “underweight” rating to an “equal weight” rating and raised their target price for the company from $22.00 to $37.00 in a report on Wednesday, October 9th. The Goldman Sachs Group boosted their price objective on shares of Affirm from $46.00 to $54.00 and gave the company a “buy” rating in a research report on Monday, October 14th. Wells Fargo & Company raised shares of Affirm from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $40.00 to $52.00 in a research note on Friday, October 11th. Susquehanna initiated coverage on Affirm in a report on Friday, September 20th. They set a “positive” rating and a $52.00 price objective on the stock. Finally, Barclays boosted their price objective on shares of Affirm from $50.00 to $54.00 and gave the company an “overweight” rating in a research note on Monday, September 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $43.08.

Affirm Stock Down 1.9 %

NASDAQ:AFRM traded down $0.81 on Tuesday, reaching $41.31. The stock had a trading volume of 706,131 shares, compared to its average volume of 8,679,919. Affirm Holdings, Inc. has a 12-month low of $16.50 and a 12-month high of $52.48. The stock has a market cap of $12.77 billion, a P/E ratio of -18.89 and a beta of 3.50. The company has a current ratio of 13.07, a quick ratio of 13.07 and a debt-to-equity ratio of 2.41. The company has a 50-day moving average of $40.82 and a 200 day moving average of $34.00.

Affirm (NASDAQ:AFRM) last posted its quarterly earnings data on Wednesday, August 28th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.31. Affirm had a negative return on equity of 15.55% and a negative net margin of 22.29%. The company had revenue of $659.19 million for the quarter, compared to the consensus estimate of $599.50 million. On average, research analysts predict that Affirm Holdings, Inc. will post -0.82 earnings per share for the current year.

About Affirm

Affirm Holdings, Inc operates a platform for digital and mobile-first commerce in the United States, Canada, and internationally. The company's platform includes point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. Its commerce platform, agreements with originating banks, and capital markets partners enables consumers to pay for a purchase over time with terms ranging up to 60 months.